UNITY Biotechnology completes enrollment in Phase 2 ENVISION study of UBX1325 for Wet Age-related macular degeneration
Due to the high interest shown in the study, 51 patients were enrolled. This is a 10% increase over target.
Data for 16 weeks is expected in Q1 2023, and data for 24 weeks in Q2 2020.
SOUTH SAN FRANCISCO, Calif., September 19, 2022 (GLOBE NEWSWIRE) — UNITY Biotechnology, Inc. (NASDAQ: UBX), a biotechnology firm developing therapeutics to stop, halt, and reverse diseases of aging, completed enrollment for its ENVISION Phase 2 clinical study of UBX1325 among patients with wet AMD. This study is an active comparison, comparing the efficacy between two doses UBX1325 and every other month treatment of aflibercept for 24 weeks.
Source:
https://ir.unitybiotechnology.com/news-releases/news-release-details/unity-biotechnology-completes-enrollment-phase-2-envision-study
